News

AstraZeneca buys Omthera
Enlarge image

BusinessUKSwedenIrelandGermanyNorway

AstraZeneca buys Omthera

29.05.2013 - AstraZeneca has filled its pipeline with a Phase III fish oil cardioprotective drug, taking over Omthera Pharmaceuticals for $443m.

The British-Swedish drug giant will pay Omthera $12.70 per share, or approximately $323 million, a premium of 88% to Omthera's closing price on Friday. In addition, Omthera shareholders will get "contingent value rights" (CVRs) of up to approximately $4.70 per share, or $120 million in total, depending on the success of Omthera's experimental fish oil-derived medicine Epanova to treat patients with very high triglyceride levels. Epanova is a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 

The expansion into the cardiovascular market pitches AstraZeneca into competition with rivals including Irish Amarin, British Glaxo SmithKline that is marketing the $917m fish-oil derived medicine Lovaza or Geman BASF, who has taken over Norwegian Pronova. Omthera's drug is ready to be filed for US approval and could be combined with AstraZeneca's cholesterol fighter Crestor.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/astrazeneca-buys-omthera.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE6.55 EUR9.17%
  • WILEX4.29 EUR5.41%
  • VITA 345.75 EUR1.77%

FLOP

  • EPIGENOMICS5.51 EUR-3.67%
  • BASILEA126.80 CHF-3.43%
  • BAYER129.15 EUR-3.19%

TOP

  • SYNGENTA425.50 CHF35.3%
  • EVOLVA1.79 CHF13.3%
  • BASILEA126.80 CHF13.1%

FLOP

  • CYTOS0.64 CHF-36.6%
  • MEDIGENE8.30 EUR-24.3%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • WILEX4.29 EUR436.2%
  • SANTHERA90.35 CHF330.2%
  • FORMYCON29.00 EUR322.7%

FLOP

  • MOLOGEN4.93 EUR-53.7%
  • BIOFRONTERA2.25 EUR-26.9%
  • PAION2.54 EUR-26.8%

No liability assumed, Date: 30.05.2015